SEC Tracker
Get the app

CVRx CVRX

CVRx reports third quarter 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Total revenue for Q3 2026 was $13.8 million
  2. U.S. revenue decreased 4% to $13.0 million
  3. Active implanting centers in the U.S. increased to 262
  4. Net loss for Q3 2026 was $14.2 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when CVRx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Venus Concept VERO
  2. LENSAR LNSR public float $113M, Jun 30, 2025
  3. TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
  4. KORU Medical Systems KRMD public float $119M, Jun 30, 2025
  5. InfuSystem Holdings INFU public float $122M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.